DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-956/SLR-039

Amersham Health
Attention: Paula Clark
Associate, Regulatory Affairs
101 Carnegie Center
Princeton, NJ 08540-6231

Dear Ms. Clark:

Please refer to your supplemental new drug application dated May 6, 1992, received May 11, 1992, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Omnipaque® (iohexol) Injection.

We acknowledge receipt of your submissions dated April 29, September 9 and 15, 1993; April 7 and 11, May 26, 1994; and June 10, 1996. We also acknowledge receipt of your submission dated December 17, 2002, withdrawing these amendments.

This "Changes Being Effected" supplemental new drug application provides for the following changes:

1. **Section 1, PRECAUTIONS-General,** 3rd paragraph: "The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered (see ADVERSE REACTIONS)" is changed to "The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid, cardiovascular or central nervous system reactions, should always be considered (see ADVERSE REACTIONS)".

2. **Section 1, ADVERSE REACTIONS-General Adverse Reactions to Contrast Media**, 4th paragraph: "CNS Irritation: Mild and transitory … echoacousia, echolalia, asterixis, and dysphasia have occurred" is changed to "CNS Irritation: Mild and transitory … echoacousia, echolalia, asterixis, cerebral hemorrhage, and dysphasia have occurred".

   8th paragraph**:** "In general, the reactions which are … However, severe, life-threatening, anaphylactoid and fatal reactions, mostly of cardiovascular origin, have occurred" is changed to "In general, the reactions which are … However, severe, life-threatening, anaphylactoid and fatal reactions, mostly of cardiovascular origin and central nervous system origin, have occurred".

3. **Section III, INDIVIDUAL INDICATIONS AND USAGE, Adverse Reactions**, 1st paragraph: "Oral administration of OMNIPAQUE… It should be noted that serious or anaphylactoid reactions that may occur with intravascular iodinated media are theoretically possible following administration by other routes" is changed to "Oral administration of OMNIPAQUE… It should be noted that serious or anaphylactoid reactions that may occur

with intravascular iodinated media are possible following administration by other routes".

4. **Section II, ADVERSE REACTIONS: Intravascular - General,** 3rd paragraph**, Nervous System:** "blurred vision" has been removed from the third line because it is mentioned on the second line.

5. **Section III, ARTHROGRAPHY, Adverse Reactions,** 3rd paragraph, **Skin and appendages:** the word "at" has been added to read as follows: "Hematoma, at injection site (0.7%)".

6. **HOW SUPPLIED:** The Sanofi Winthrop name and logo have been added. Omnipaque 240 (200ml fill/200ml) and Omnipaque 300 (150ml fill/200ml bottle) are no longer packaged with infusion sets, therefore the NDC numbers have changed.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions listed below.

In the **HOW SUPPLIED** section: We reference your correspondence dated October 15, 2001, in which you notified the Food and Drug Administration that your corporate name was changed to Amersham Health. Therefore, the Amersham Health name and logo is to be used instead of the Sanofi Winthrop name and logo; updated NDC #s are to be used for Omnipaque 240 (200ml fill/200ml) and Omnipaque 300 (150ml fill/200ml bottle).

The final printed labeling (FPL) must include all previous revisions as reflected in the most recently approved package insert, as well as the minor editorial revisions indicated. These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 18-956/SLR-039." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lynn Panholzer, Pharm.D., Regulatory Project Manager, at (301) 827-3247.

Sincerely,

{See appended electronic signature page}

Patricia Y. Love, M.D., M.B.A.
Director
Division of Medical Imaging and Radiopharmaceutical Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Patricia Love
12/23/02 10:22:49 AM